TRAVIS DEANGELIS: Open Payments
NPI 1598506990 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 20 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $92 |
| Alkermes, Inc. | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $52 |
| ABBVIE INC. | 2 | $51 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: Auvelity, INVEGA SUSTENNA, VRAYLAR, INGREZZA, COBENFY, VIVITROL, ARISTADA, UZEDY.
Industry payments across CO — which companies pay providers there.
